Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics has appointed Professor Phillipa Hay, an esteemed academic psychiatrist with significant contributions to eating disorder and obesity research, to its Scientific Advisory Board. Professor Hay’s expertise in psychedelic treatments for eating disorders and her extensive publication record are anticipated to support Tryp Therapeutics’ clinical development pathway. The biotech company is advancing its proprietary intravenous psilocin formulation, aiming to address unmet medical needs alongside psychotherapy.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.